Screening and Testing
Women from various racial and ethnic backgrounds, particularly Black women, had a higher risk of biopsy delays after an abnormal mammogram than white women.
Over the last 10 years, women of color, as well as women with less education and lower incomes, have had less access to 3D screening mammograms compared to white women and women who are more educated and well-off financially.
A Swedish study found 3D screening mammograms reduce the rate of interval cancers — cancers detected in between routine screening — compared to 2D digital mammograms.
After coming to a halt at the beginning of the pandemic, numbers of screening mammograms are climbing back up to nearly pre-pandemic levels, but rates among Hispanic and Asian women continue to be lower than average.
Women of color and women living in rural areas were more likely to miss regular screening mammograms during the COVID-19 pandemic than white and urban women.
Considering information about the clinical risk of recurrence of early-stage breast cancer along with the Oncotype DX Recurrence Score results can help refine which women age 50 and younger diagnosed with early-stage hormone-receptor-positive, HER2-negative breast cancer that has not spread to the lymph nodes with a Recurrence Score of 16 to 25 will benefit from chemotherapy.
The prospective PlanB study has found that women with a Recurrence Score of 11 or lower who skipped chemotherapy based on the Recurrence Score had excellent 5-year survival rates.
A study suggests the MammaPrint test can help estimate the risk of recurrence after surgery for early-stage disease.
The debate about the benefits of screening mammograms for women younger than 50 goes back at least as far as 1969.
A test that measures circulating tumor cells in the blood may help doctors more accurately determine the risk of breast cancer recurrence.
Women with ATM, CHEK2, or PALB2 mutations may benefit from starting annual breast cancer screening with MRI between the ages and 30 to 35 and an annual MRI and mammogram starting at age 40.
New research suggests that having mammograms twice per year after lumpectomy finds a cancer recurrence (or a new cancer) earlier than only one mammogram per year after surgery.
Many women treated for childhood cancer with chest radiation therapy aren't getting recommended breast cancer screening.
Getting regular mammograms reduces the risk of advanced breast cancer.
More than 70% of deaths from breast cancer are in women aged 40 to 49 who don't get regular mammograms, a large study suggests.
Study adds more evidence to research suggesting that 3-D mammograms find more cancers than traditional 2-D mammograms.
A study has found that genetic counseling over the phone is equal to in-person genetic counseling for women at high risk for a genetic mutation that would raise their risk of breast or ovarian cancer.
Ultrasound doesn't add benefits beyond mammograms in diagnosing male breast cancer.
Research suggests that women who receive false-positive mammogram results may be more likely to put off their next scheduled mammogram.
A study has found that most women now have multigene testing after a breast cancer diagnosis, but this genetic testing is happening later in the treatment plan than testing for only BRCA1 or BRCA2 mutations.
The American Society of Breast Surgeons' new breast cancer screening recommendations say women at average risk should start having annual mammograms at age 40.
MRI monitoring in women previously diagnosed with breast cancer finds more cancers than mammography, but also leads to more biopsies.
Research shows that breast self-exam is an important cancer detection tool for young women, especially young women at high risk for breast cancer.
Women diagnosed with breast cancer who had regular mammograms had a 60% lower risk of dying from the disease in the 10 years after diagnosis and a 47% lower risk of dying from the disease in the 20 years after diagnosis compared to women who didn't have regular screening.